Chapters

Transcript

Video

If MET amplification is documented in NSCLC, why is crizotinib considered by the NCCN to have "targeted activity" against this tumor profile? What high activity in patients with this genetic alteration?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Paul Mitchell, BHB, MBChB, FRACP, MD

Paul Mitchell, BHB, MBChB, FRACP, MD

Associate Professor
Senior Specialist
Austin Health Cancer Services
Director, North Eastern Metropolitan Integrated Cancer Services (NEMICS)
Melbourne, Australia